Lechapt-Zalcman Emmanuèle, Karanian-Philippe Marie, Rousseau Audrey
CHU de Caen, Laboratoire d'anatomie pathologique, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France.
Bull Cancer. 2013 Jan 1;100(1):29-34. doi: 10.1684/bdc.2012.1677.
Diagnosis of brain metastases should aim to identify anatomoclinical entities for which a specific treatment is more accurate. Growing numbers of targeted therapies have shown to be effective against specific cancers. Several studies have reported that targeted therapies are capable of reducing brain metastases in melanoma or non small cell lung cancer (NSCLC), sometimes with a high dramatic response. These results have clearly impacted routine neuropathological practice, leading to multidisciplinary strategy management of brain metastases tissues. In accordance with the recommendations of French National Cancer Institute (INCa), the pathologist develops appropriate strategies for molecular and immunohistochemical analysis, in order to provide results as soon as possible.